Prelude Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Prelude Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-8,000	Closed	-$120K	–	1752
2018 Q1	$120K	Buy	+8,000	New	+$122K	0.01%	822
2017 Q4	–	Sell	-8,500	Closed	-$128K	–	1460
2017 Q3	$128K	Buy	+8,500	New	+$112K	0.01%	798
2016 Q4	–	Sell	-1,800	Closed	-$13K	–	1625
2016 Q3	$13K	Buy	+1,800	New	+$12.2K	﹤0.01%	1400
2016 Q1	–	Sell	-5,000	Closed	-$49K	–	1341
2015 Q4	$49K	Buy	+5,000	New	+$45.1K	0.01%	1050

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Prelude Capital Management's FOLD Position: Q1 2026 in Review

Prelude Capital Management increased its Amicus Therapeutics (FOLD) stake by 83% in Q1 2026, buying an estimated $4.16M and bringing the position to 639,885 shares worth $9.25M. The position accounts for 0.71% of the portfolio, ranked #20.

Prelude Capital Management first reported a position in FOLD in Q3 2014 and has held it in 25 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Prelude Capital Management held 639,885 shares of Amicus Therapeutics worth $9.25M as of Q1 2026.
Prelude Capital Management bought 290,471 Amicus Therapeutics shares in Q1 2026, an estimated $4.16M.
Amicus Therapeutics made up 0.71% of Prelude Capital Management's portfolio in Q1 2026, its #20 holding.
Prelude Capital Management first reported a position in Amicus Therapeutics in Q3 2014 and has held it in 25 quarters since.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.